Canada markets close in 56 minutes

Small Pharma Inc. (DMT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1600+0.0050 (+3.23%)
As of 03:03PM EDT. Market open.
Full screen
Previous Close0.1550
Bid0.1550 x N/A
Ask0.1600 x N/A
Day's Range0.1450 - 0.1600
52 Week Range0.0600 - 0.2200
Avg. Volume350,681
Market Cap51.45M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • GlobeNewswire

    Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

    Efficacy Chart Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy • Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression • No apparent differences in the safety and tolerability profile of SPL026 (DMT) following admin

  • Newsfile

    Cybin to Acquire Small Pharma Inc.

    - All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pend

  • GlobeNewswire

    Small Pharma Reports Fiscal First Quarter 2024 Highlights

    • Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date • SPL026 Phase IIa clinical trial results well-received at several international scientific conferences • Anticipated cash runway to at least Q4 2024 following recent operational restructuring LONDON, July 27, 2023 (GLOBE NEWSWI